The Clinical Research Of TACE Combined With HIFU Ablation On Liver Cancer Of Effects On The Immune Function

Objective:To study transcatheter artery chemoembolization (TACE) combined with high-intensity focused ultrasound (HIFU) ablation on liver cancer of effects on the immune function. Provide certain theoretical basis for TACE combined with HIFU ablation treatment of liver cancer. Discussion TACE combined with HIFU treatment effect on the immune function of liver cancer and its clinical significance, for TACE combined with HIFU ablation treatment clinical application value to provide the scientific basis for the treatment of liver cancer.Methods:Collected in our hospital in patients with liver cancer,46cases were divided into conventional TACE solo group (control group) and TACE combined with HIFU ablation treatment group (experimental group), each group had23patients. Observe the curative effect of two groups of patients and preoperative and postoperative1,3,6,12months immune index (CD3+T cells and CD4+T cells and CD8+T cells, NK cells, CD4+/CD8+T cells, T cell ratio) and the change of clinical symptoms.Results:The control group after1month compared with preoperative CD3+, CD4+and NK ratio and CD4+/CD8+T ratio higher, the percentage of CD8+Tlower; Postoperative3months with preoperative comparison of CD3+, CD4+and NK and CD4+/CD8+ratio increased slightly, the percentage of CD8+T slightly lower; After6months compared with preoperative CD3+,CD4+and NK and CD4+/CD8+ratio increased slightly, the proportion of the CD8+, slightly lower; After12months compared with preoperative CD3+, CD4+and NK and CD4+/CD8+ratio is slightly lower, CD8+proportion increased slightly. Experimental group after1month compared with preoperative CD3+, CD4+and NK and CD4+/CD8+ratio increased significantly, the percentage of CD8+significantly lower; Postoperative3months compared with the preoperative CD3+, CD4+and NK proportion and CD4+/CD8+ratio increased significantly, the percentage of CD8+significantly reduced; After6months compared with preoperative CD3+, CD4+and NK and CD4+/CD8+ratio increased slightly, slightly lower proportion of the CD8+, After12months compared with preoperative CD3+, CD4+and NK and CD4+/CD8+ratio increased slightly, CD8+ratio is slightly lower. Compare the two groups datas, the experimental group after1month,3months increased compared with control group, with statistical significance,6and12months, with slightly higher than the control group, the difference was not statistically significant. Postoperative clinical symptoms in patients with changes as follows:fatigue obviously improve the combination group was87.5%(14/16), while the control group46.7%(7/15); Thin obviously improve the treatment group was75%(9/12), while the control group46.15%(6/13); NaCha obviously improve accounted for84.61%(13/15), while the control group41.67%(5/12); Liver area pain relief obvious in the treatment group was75%(11/13), while the control group42.85%(6/14).The experimental group and control group after3months,6months,12months of survival rates were100.00%,91.31%,78.26%and100.00%,69.60%,56.52%, of which Media Time Survival for15months and12months respectively, the difference was statistically significant (P<0.05).Conclusion:1, The TACE treatment on the immune function of patients with postoperative1month obvious enhancement,3,6,12months after treatment the immune function change is not obvious.2, TACE combined with HIFU ablation compared with solo TACE treatment on the immune function of patients with postoperative1,3months enhanced obviously, postoperative6,12months the immune function was similar with TACE treatment alone.3, TACE combined with HIFU ablation in the treatment of liver cancer patients to improve patients’ clinical symptoms superior to solo TACE treatment.